Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma

por Huan Zhang, Guangyao Shan, Benjie Cai, Guoshu Bi, Zhencong Chen, Jiaqi Liang, Valeria Besskaya, Yuansheng Zheng, Weigang Guo, Lin Wang, Songtao Xu, Cheng Zhan
Publicado 2021

ALK rearranged non–small cell lung carcinoma with EML4-NTRK3 fusion as a possible mechanism of resistance to third-generation ALK inhibitors

por Elena Corral de la Fuente, Amparo Benito Berlinches, Ana Gomez Rueda, María Eugenia Olmedo García, Yolanda Lage Alfranca, Margaret Lario, Almudena Santón Roldán, Pilar Garrido
Publicado 2021

Manejo clínico y terapéutico de un tumor fibroso pleural con translocación de ALK

por Patricia Cruz-Castellanos, Laura Gutiérrez-Sainz, Julia Villamayor, María I. Esteban, Alberto Peláez, Francisco J. de Castro
Publicado 2021

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature

por Deng L, Sharma J, Ravera E, Halmos B, Cheng H
Publicado 2018

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report

por Shuluan Li, Pei Zhang, Tianyu Wang, Jie Wang, Jianchun Duan
Publicado 2021

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation

por Zhu VW, Schrock AB, Bosemani T, Benn BS, Ali SM, Ou SI
Publicado 2018

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors

por Schrock AB, Madison R, Rosenzweig M, Allen JM, Erlich RL, Wang SY, Chidiac T, Reddy VS, Riess JW, Yassa AE, Shakir A, Miller VA, Alexander BM, Venstrom J, McGregor K, Ali SM
Publicado 2020

Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer

por Anna M. Wulf, Marcela M. Moreno, Chloé Paka, Alexandra Rampasekova, Karen J. Liu
Publicado 2021

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives

por Giroux Leprieur E, Fallet V, Cadranel J, Wislez M
Publicado 2016

Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibito...

por Wen Dong, Pengfei Lei, Xin Liu, Qin Li, Xiangyang Cheng
Publicado 2021

Gene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma

por Daugrois Camille, Bessiere Chloé, Dejean Sébastien, Anton Leberre Véronique, Commes Thérèse, Stephane Pyronnet, Pierre Brousset, Estelle Espinos, Brugiere Laurence, Fabienne Meggetto, Laurence Lamant
Publicado 2021

Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials

por Hao-chuan Ma, Yi-hong Liu, Kai-lin Ding, Yu-feng Liu, Wen-jie Zhao, Yan-juan Zhu, Xue-song Chang, Ya-dong Chen, Zhen-zhen Xiao, Ya-ya Yu, Rui Zhou, Hai-bo Zhang
Publicado 2021

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases

por Zhu VW, Nagasaka M, Kubota T, Raval K, Robinette N, Armas O, Al-Holou W, Ou SI
Publicado 2020

The Dual Effect of the BMP9–ALK1 Pathway in Blood Vessels: An Opportunity for Cancer Therapy Improvement?

por Blanca Ayuso-Íñigo, Lucía Méndez-García, Miguel Pericacho, José M. Muñoz-Félix
Publicado 2021

Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rear...

por Liang L, Mao M, Wu L, Chen T, Lyu J, Wang Q, Li T
Publicado 2021

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations

por Whitney E. Lewis, PharmD, Lingzhi Hong, MD, PhD, Frank E. Mott, MD, George Simon, MD, Carol C. Wu, MD, Waree Rinsurongkawong, MS, MS, PhD, J. Jack Lee, MS, PhD, Vincent K. Lam, MD, John V. Heymach, MD, PhD, Jianjun Zhang, MD, PhD, Xiuning Le, MD, PhD
Publicado 2021

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib

por Jain RK, Chen H
Publicado 2017

A Simple Inner-Stopper Guarded Trephine for Creation of Uniform Keratectomy Wounds in Rodents

por Peter B. Le, Fang Chen, David Myung
Publicado 2021

Crizotinib and ceritinib trigger immunogenic cell death via on-target effects

por Adriana Petrazzuolo, Maria Perez-Lanzon, Peng Liu, M. Chiara Maiuri, Guido Kroemer
Publicado 2021

Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer

por Legius B, Van Den Broecke S, Muylle I, Ninane V
Publicado 2016